Zoetis (ZTS) Given “Buy” Rating at Jefferies Group

Zoetis (NYSE:ZTS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Group in a research note issued to investors on Friday. They presently have a $96.00 target price on the stock. Jefferies Group’s price objective suggests a potential upside of 14.87% from the stock’s previous close. Jefferies Group also issued estimates for Zoetis’ Q1 2018 earnings at $0.71 EPS, FY2018 earnings at $3.07 EPS, FY2019 earnings at $3.56 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $4.56 EPS and FY2022 earnings at $5.09 EPS.

Several other research analysts have also issued reports on the company. Morgan Stanley lowered Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price target on the stock. in a research report on Monday, March 19th. They noted that the move was a valuation call. Credit Suisse Group lifted their target price on Zoetis from $83.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, April 5th. ValuEngine upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Deutsche Bank lifted their target price on Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Friday, February 16th. Finally, Barclays set a $77.00 price target on Zoetis and gave the company a “hold” rating in a research note on Saturday, February 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $80.89.

Shares of NYSE:ZTS opened at $83.57 on Friday. Zoetis has a twelve month low of $53.00 and a twelve month high of $85.73. The company has a market cap of $40,741.90, a P/E ratio of 34.82, a price-to-earnings-growth ratio of 1.88 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.



Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the prior year, the firm posted $0.47 EPS. Zoetis’s quarterly revenue was up 14.3% compared to the same quarter last year. equities research analysts forecast that Zoetis will post 3.05 earnings per share for the current fiscal year.

In other Zoetis news, insider Roman Trawicki sold 23,885 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,952 shares of company stock worth $9,219,843. Company insiders own 0.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Chemical Bank bought a new stake in Zoetis during the fourth quarter valued at $350,000. Cambridge Investment Research Advisors Inc. lifted its position in Zoetis by 27.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock valued at $1,288,000 after acquiring an additional 3,904 shares in the last quarter. Xact Kapitalforvaltning AB lifted its position in Zoetis by 9.8% in the 4th quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock valued at $5,051,000 after acquiring an additional 6,253 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Zoetis by 31.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock valued at $9,719,000 after acquiring an additional 32,149 shares in the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA lifted its position in Zoetis by 106.2% in the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock valued at $1,807,000 after acquiring an additional 12,925 shares in the last quarter. Institutional investors and hedge funds own 92.44% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://dakotafinancialnews.com/2018/04/13/zoetis-zts-pt-set-at-96-00-by-jefferies-group.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply